VANCOUVER, Sept. 18 /CNW/ - Protox Therapeutics Inc. (TSX-V:PRX) today
announced the appointment of Dr. Martin Gleave MD, FRCSC, FACS, as the
Chairman of its Clinical Advisory Board (Urology). Dr. Gleave brings to Protox
a wealth of clinical and research experience in the field of prostate disease
and will be instrumental in providing strategic guidance as the company
advances its clinical programs for both localized prostate cancer and BPH
(enlarged prostate).
